Introduction The Fear-Avoidance (FA) model aims to explain how an acute pain experience can develop into a persistent state. The FA model considers five core components: kinesiophobia, pain-related fear, catastrophisation, victimisation, and interpersonal social environment. Amongst these, kinesiophobia, tends to dominate the literature on chronic musculoskeletal pain. As a result, current reviews have not considered the other core components of the FA model when exploring its interventions. Moreover, several synonyms of the term kinesiophobia is not reflected in their search strategies. Coupled with the preference of particular study designs and outcome measures, this systematic review aims to provide and characterise an overview of treatment interventions that consider all study designs, relevant outcome measures, FA components, and FA component synonyms. Methods and analysis Eligible studies will be in English or with an available English translation from 1970 onwards. Databases to be searched include Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, The Allied and Complementary Database (AMED), PEDro, Web of Science, and grey literature. We will include studies involving participants ≥18 years old with chronic musculoskeletal pain, and interventions targeting FA and/or its components. Three review authors will independently screen papers using preestablished eligibility criteria and conduct assessments of risk of bias, with a fourth independent researcher employed to resolve disagreements where found. Qualitative synthesis techniques will be used to characterise the interventions. Patient and Public Involvement (PPI) has been utilised to develop this protocol and will be conducted following completion of the systematic review to discuss and reflect on the findings. Ethics and dissemination This systematic review does not require ethical approval as existing data will be used and the PPI to be conducted is an involvement activity rather than study data. The results will be disseminated through a peer-reviewed journal and via national and international conferences. Prospero registration number [this protocol will be registered following peer review]

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A as systematic review protocol.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.